Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Zelira Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
No marijuana is ok for pregnant women, not even for morning sickness
Experts
Scopo’s health powerplays: You’re all going to the pot, literally
Health & Biotech
COVID-19 hasn’t hurt cannabis clinical trials … much
Health & Biotech
Zelira, PolyNovo prove even a pandemic can’t stand in the way of good clinical results
Health & Biotech
Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start
News
Cannabis: Another German importer wants Little Green Pharma’s products
Health & Biotech
Zelira is worshipping at the FDA altar hoping it will smite enemies
Health & Biotech
Here’s how to pick a successful drug out of the 99pc of failures
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Zelira’s primed to launch the world’s first clinically validated cannabis product for insomnia
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Compumedics wins FDA approval for its brain scanners, leaps +20pc
News
Lunchtime ASX small cap wrap: Who’s getting locked in a stalemate today?
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Cannabis: Elixinol Global kills medical pot, holds fire sale for Aussie hemp
Health & Biotech
My bank balance is bigger than yours: biotech quarterlies
Health & Biotech
